Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > injectable cytotoxic drugs market
Get a free sample of Injectable Cytotoxic Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Injectable Cytotoxic Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Injectable Cytotoxic Drugs Market size was valued at USD 9.7 billion in 2023 and is anticipated to register over 5.8% CAGR from 2024 – 2032. Increasing incidence of cancer and rheumatoid arthritis, growing regulatory approvals for injectable cytotoxic drugs, and increasing investments for the development of precision oncology therapies is driving the revenue growth in the injectable cytotoxic market. Additionally, rapid increase in cancer care facilities globally is also contributing to an increasing demand for cancer therapeutics such as cytotoxic drugs.
Injectable cytotoxic drugs are prescription drugs used as a first line of treatment during the treatment of cancer and other diseases. Majority of these drugs are off-patent and are commercially available as a generic. These drugs are administered through injection or infusion directly into the bloodstream and destroy rapidly diving cells such as cancer cells.
The global market size for injectable cytotoxic drugs was valued at USD 9.7 billion in 2023 and is anticipated to showcase 5.8% CAGR from 2024
The antimetabolites drug class segment of the injectable cytotoxic drugs market held 44.2% share in 2023 and will expand rapidly through 2032, attributed to their wide use in anti-cancer therapies.
North America market accounted for 42.2% share in 2023 and is predicted to reach USD 6.6 billion by 2032, driven by the presence of large number of pharmaceutical manufacturers offering advanced treatment options for cancer treatment.
Abbvie Inc, Accord Healthcare, Amgen, Inc.,Baxter International Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Fresenius Kabi AG among others.